P/E at 34.72 vs Industry's 31.34: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Norms

The current P/E ratio of Sun Pharmaceutical Industries Ltd at 34.72 stands approximately 10.8% above the industry average of 31.34. This premium suggests that investors are willing to pay more for each rupee of earnings relative to its peers in the Pharmaceuticals & Biotechnology sector. Such a valuation gap often reflects expectations of superior earnings quality, growth prospects, or market positioning. However, the premium is not excessive compared to some high-growth pharma peers, indicating a balanced valuation stance. The question remains — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating? This valuation context is crucial for interpreting the recent rating reassessment.

Performance Across Timeframes: Mixed Signals

Examining the stock’s returns reveals a nuanced picture. Over the past year, Sun Pharmaceutical Industries Ltd has declined by 3.86%, outperforming the Sensex’s 6.47% fall. This relative resilience over a longer horizon contrasts with the sharper declines seen in shorter periods. The three-month return of -4.76% is notably better than the Sensex’s -16.44%, yet it still marks a negative trend for the stock itself. Year-to-date, the stock is down 4.17%, again outperforming the broader market’s 15.91% loss. This pattern suggests that while the stock has weathered broader market volatility better than many peers, recent momentum has turned negative — is this a temporary setback or a sign of deeper weakness?

Moving Average Configuration: Bearish Territory

The technical picture for Sun Pharmaceutical Industries Ltd is decidedly bearish. The stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day. This alignment indicates sustained downward pressure and a lack of short-term recovery signals. The absence of any bounce above short-term averages suggests that the recent declines are part of a broader downtrend rather than a brief correction. The stock’s failure to reclaim these technical levels raises the question — is this a genuine recovery or a dead-cat bounce? The moving average configuration provides the clearest answer.

Relative Performance: Outperforming Despite Downtrend

Despite the recent technical weakness, Sun Pharmaceutical Industries Ltd has outperformed the Sensex across multiple timeframes. Over one week, the stock declined 8.18% compared to the Sensex’s 4.80% fall, indicating short-term underperformance. However, over one month and three months, the stock’s losses of 5.97% and 4.76% respectively are significantly less severe than the Sensex’s declines of 10.69% and 16.44%. This relative outperformance extends to the year-to-date period as well. The stock’s resilience relative to the broader market suggests underlying strength in fundamentals or sector positioning, even as it faces near-term headwinds. This raises the analytical question — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Sector Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has experienced mixed results recently, with a combination of positive, flat, and negative performances among constituent stocks. Sun Pharmaceutical Industries Ltd’s relative outperformance against the Sensex and its sector peers highlights its standing as a large-cap leader within the industry. The sector’s overall volatility and regulatory challenges have contributed to the cautious sentiment, but the company’s valuation premium and historical performance over three and five years — 67.63% and 169.79% respectively — underscore its long-term growth credentials. This sector backdrop is essential for contextualising the company’s current rating update.

Rating Context: Previously Hold, Now Reassessed

MarketsMOJO previously rated Sun Pharmaceutical Industries Ltd as Hold, with a Mojo Score of 72.0. The rating was updated on 23 Feb 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technicals. The data-driven approach considers the valuation premium, relative performance, and moving average configuration to arrive at a nuanced view. The updated rating invites investors to revisit their stance — what is the current rating for Sun Pharmaceutical Industries Ltd?

Conclusion: A Complex Picture Emerges

The data on Sun Pharmaceutical Industries Ltd paints a complex picture. The stock trades at a moderate premium to its sector, reflecting investor confidence in its earnings quality and market position. Its relative outperformance against the Sensex over one year and three months contrasts with a bearish technical setup, as it remains below all key moving averages. The recent rating reassessment from Hold invites a fresh evaluation of the stock’s prospects in light of these mixed signals. Investors must weigh the valuation premium against the short-term momentum challenges — should they hold, buy more, or reconsider their position?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →